X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Budget 2012-13: Impact on Pharma sector - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Mar 21, 2012

    Budget 2012-13: Impact on Pharma sector

    The honorable finance minister presented the budget for the financial year 2012-2013 on 16th March 2012. For the stock markets, it turned out to be a non-event. However, few budget proposals have affected various sectors in a small way. In this article, we discuss the impact of budget proposals on Indian pharmaceutical sector.

    Major budget proposals that affected the pharma companies

    1. The budget has proposed to tax all companies at the minimum alternate tax (MAT) of 18.5%. This will also include the partnerships firms based in the special economic zones (SEZ). Sun pharma will face a major hit as two of its facilities in Jammu and Sikkim enjoy benefits by avoidance of taxes as they do not pay the MAT.

    2. The budget also increased the excise duty on drug formulation and Active Pharma Ingredients (API) from 5% to 6% and 10% to 12% respectively. However, the companies have manufacturing facilities in the SEZ area will not be affected as they do not have to pay the excise duties. According to us, this will not have much impact on most of the companies in the pharmaceutical space.

    3. The budget has further announced to continue the deduction of 200% for in-house R&D for another 5 years. The previous scheme was supposed to expire on 31st March 2012 which now stands extended to 31st March 2017. Large pharma players like Dr Reddy, Sun Pharma, Glenmark and Biocon will thereby continue their tax benefits on R&D expenses.

    4. Further there were certain announcements for capital expenditure on large hospitals and it is expected to benefit the players who are into managing hospitals.
    Overall, the budget did not have anything encouraging for the pharmaceutical sector. However, the fact that there were no negative surprises itself has come as relief. The extension of deductions for the in-house R&D was a very good move and this will go a long way to incentivize the R&D within Indian pharmaceutical sector.

     

     

    Equitymaster requests your view! Post a comment on "Budget 2012-13: Impact on Pharma sector". Click here!

      
     

    More Views on News

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

    Nov 7, 2016

    Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

    Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    BIOCON LTD SHARE PRICE


    Aug 23, 2017 (Close)

    TRACK BIOCON LTD

    • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    BIOCON LTD 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE BIOCON LTD WITH

    MARKET STATS